RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma.
Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
MicroRNAs(miRNAs)是微小且高度保守的非编码RNA,通过结合靶mRNA的3‘-UTR在转录后水平调控基因表达。多项研究发现,miR-195在肝细胞癌(HCC)的细胞增殖、周期和凋亡调控中发挥不可忽视的作用。
在此,我们构建了共载miR-195和Chlorine e6(Ce6)的NBs(纳米泡),利用NBs作为载体将miR-195和Ce6递送至小鼠肿瘤模型。
我们的结果表明,通过上调miR-195表达,PD-1与PD-L1之间的结合被阻断。治疗组中CTL(细胞毒性T细胞)免疫活性分析高于对照组。
同时,Ce6作为声敏剂诱导SDT(声动力治疗),并通过产生ROS触发肿瘤细胞的ICD(免疫原性细胞死亡)。近期研究发现,ICD可能进一步增强针对PD-L1的抗肿瘤免疫。
结果表明,联合治疗有效刺激了T细胞浸润、自然杀伤(NK)细胞活化以及树突状细胞(DCs)成熟,且联合治疗组表现出最高的CTL杀伤活性。这些结果表明,通过SDT诱导的肿瘤细胞ICD与miR-195上调介导的PD-1/PD-L1免疫检查点阻断的联合,触发了更强的抗肿瘤免疫。
总之,我们成功构建了一种高效的递送系统,具有为协同免疫治疗提供新策略的巨大潜力。
MicroRNAs (miRNAs) is the tiny and highly conserved noncoding RNAs, regulate gene expression at the post-transcriptional level by binding to the 3'-UTR of target mRNAs. Several studies found that miR-195 plays an unavoidable role in the regulation of cell proliferation, cycle and apoptosis in hepatocellular carcinoma (HCC).
Here, we constructed miR-195 and Chlorine e6 (Ce6) co-loading NBs (nanobubbles), making use of NBs as carriers to deliver miR-195 and Ce6 to mouse tumor models.
Our results showed that the binding between PD-1 and PD-L1 was blocked by upregulating miR-195 expression. The analysis of CTL (Cytotoxic T Cell) immune activity in the treatment group was higher than the control group. Simultaneously, Ce6 was used as sonosensitizer to induce SDT (sonodynamic therapy) and trigger ICD (immunogenic cell death) of tumor cell via generation of ROS. Recent studies have found that ICD may further enhance anti-tumor immunity against PD-L1.
Results indicated that combination treatment effectively stimulated infiltration of T cell and the activation of natural killer (NK) cells as well as the maturation of dendritic cells (DCs), and the combination treatment group exibited the highest CTL killing activity. These results indicate that a stronger antitumor immunity was triggered via combination of SDT-induced tumor cell ICD and immune checkpoint blockade of PD-1/PD-L1 mediated by upregulation of miR-195.
In conclusion, we have successfully constructed an efficient delivery system with great potential to provide a new strategy for synergistic immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。